Recent HOTH News
- Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide • PR Newswire (US) • 04/14/2026 11:00:00 AM
- Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide • PR Newswire (US) • 04/13/2026 09:23:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:18:12 PM
- Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering • PR Newswire (US) • 04/02/2026 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/02/2026 05:39:13 PM
- Hoth Therapeutics Announces $2.0 Million Registered Direct Offering • PR Newswire (US) • 04/01/2026 05:52:00 PM
- Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six • PR Newswire (US) • 04/01/2026 12:14:00 PM
- Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology • PR Newswire (US) • 03/31/2026 12:07:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/27/2026 08:58:52 PM
- Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery • PR Newswire (US) • 03/26/2026 12:30:00 PM
- Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption • PR Newswire (US) • 03/24/2026 12:13:00 PM
- Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model • PR Newswire (US) • 03/10/2026 12:13:00 PM
- Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program • PR Newswire (US) • 03/04/2026 01:31:00 PM
- HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES • PR Newswire (US) • 02/24/2026 09:15:00 PM
- Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases • PR Newswire (US) • 02/12/2026 01:33:00 PM
- Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model • PR Newswire (US) • 02/10/2026 01:30:00 PM
- Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets • PR Newswire (US) • 02/05/2026 01:03:00 PM
- Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients • PR Newswire (US) • 01/22/2026 01:13:00 PM
- Hoth Therapeutics gains after winning China patent for HT-KIT cancer program • IH Market News • 01/21/2026 03:43:57 PM
- Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position • PR Newswire (US) • 01/21/2026 01:13:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2026 01:04:57 PM
- Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation • PR Newswire (US) • 01/15/2026 01:17:00 PM
- Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform • PR Newswire (US) • 01/02/2026 01:13:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/05/2025 05:15:34 AM
- Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program • PR Newswire (US) • 12/03/2025 07:00:00 PM
